Your browser doesn't support javascript.
loading
How to triage HPV positive cases: Results of four million females.
Gultekin, Murat; Dundar, Selin; Keskinkilic, Bekir; Turkyilmaz, Murat; Ozgul, Nejat; Yuce, Kunter; Kara, Fatih.
Afiliação
  • Gultekin M; Hacettepe University Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Ankara, Turkey. Electronic address: gultekin@hacettepe.edu.tr.
  • Dundar S; General Directorate of Public Health, Ministry of Health of Turkey, Ankara, Turkey.
  • Keskinkilic B; General Directorate of Public Health, Ministry of Health of Turkey, Ankara, Turkey.
  • Turkyilmaz M; General Directorate of Public Health, Ministry of Health of Turkey, Ankara, Turkey.
  • Ozgul N; Hacettepe University Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Ankara, Turkey.
  • Yuce K; Hacettepe University Faculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Ankara, Turkey.
  • Kara F; General Directorate of Public Health, Ministry of Health of Turkey, Ankara, Turkey.
Gynecol Oncol ; 158(1): 105-111, 2020 07.
Article em En | MEDLINE | ID: mdl-32362567
ABSTRACT

OBJECTIVE:

To evaluate the Turkey's nationwide HPV DNA screening program on the basis of first 4 million screened women.

METHODS:

Women over age 30 were invited for screening via HPV DNA and conventional cytology. Single visit screen strategy was used to collect for both screening and triage (extended genotyping and conventional pap-smear).

RESULTS:

A total of 4,099,230 patients had attended to HPV DNA cancer screening. 4.39% were found to be HPV DNA positive. The most common HPV type was 16, followed by 51, 31, 52, 56 and 18 at all age intervals and geographic regions. Cytology results were reported as "normal" in (69.2%), "inadequate sampling" in (16.6%) and as "abnormal (≥ASC-US)" in the remaining. Current Turkish screening with HPV DNA (referral to colposcopy with HPV 16 or 18 or any smear abnormality ≥ASC-US) gives overall PPV of 24.3% for ≥CIN2. Only Pap-Smear triage revealed PPV of 26.4% for ≥ASC-US thresholds. Comparison of different triage methods for ≥CIN2+ according to different HPV genotype revealed a PPV of 32,6% for HPV 16; 15,3% for HPV 18. This figure was 34.4%, 19.3%, 15.3% and 14.0% for HPV 33, 31, 45 and 35; respectively.

CONCLUSION:

This study involves the largest series in the world summarizing a real-world experience with primary HPV DNA screening and triage with a single visit. The results show the feasibility and applicability of such screening method in developing countries with acceptable colposcopy referral rates. Among triage tests, only pap-smear seems to be effective without a need for extended genotyping.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Displasia do Colo do Útero / Neoplasias do Colo do Útero / Infecções por Papillomavirus / Alphapapillomavirus Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Adult / Female / Humans / Middle aged País/Região como assunto: Asia Idioma: En Revista: Gynecol Oncol Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Displasia do Colo do Útero / Neoplasias do Colo do Útero / Infecções por Papillomavirus / Alphapapillomavirus Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Adult / Female / Humans / Middle aged País/Região como assunto: Asia Idioma: En Revista: Gynecol Oncol Ano de publicação: 2020 Tipo de documento: Article